ArticleCVIR endovascular2026
Genicular artery embolization for refractory pain after knee arthroplasty: clinical outcomes from a retrospective pilot study.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRefractory pain after knee arthroplasty without prosthetic loosening, infection, or mechanical failure remains a therapeutic challenge for which few non-surgical options are available. Genicular artery embolization (GAE) has shown promise in knee osteoarthritis, but evidence in patients treated after arthroplasty remains limited. The aim of this study was to evaluate the technical feasibility, safety, and short- to mid-term clinical outcomes of GAE using imipenem/cilastatin (IPM/CLS) in this population.
resultsFifteen consecutive patients (9 men, 6 women; median age, 67 years) underwent GAE between January 2022 and December 2025 for refractory pain after total knee, unicompartmental, or isolated retropatellar arthroplasty. Hypervascular periarticular branches were embolized with an IPM/CLS suspension through common femoral arterial access. Outcomes were assessed using the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Total Analgesic Consumption Score (TACS) at baseline and 1, 3, 6, and 12 months. Technical success was 100%. Median NRS fell from 7.0 (interquartile range, 6.0-8.0) at baseline to 1.0 at 1 month (p < 0.001), 3.0 at 3 and 6 months, and 5.0 at 12 months (p = 0.018). Median WOMAC decreased from 32.0 to 20.0 (p = 0.032) and KOOS from 20.0 to 14.0 (p = 0.041) at 12 months. TACS improved significantly through 6 months (p ≤ 0.026); 4 of 7 patients on baseline opioids had discontinued by 12 months. At 12 months, 5 of 9 evaluable patients (56%) maintained a ≥ 2-point NRS reduction and 4 of 9 (44%) achieved a ≥ 30% reduction. Repeat embolization was performed in 3 patients (20%). No major complications occurred; minor transient adverse events occurred in 2 patients (13%): mild periarticular discomfort and self-limited skin erythema.
conclusionsIn this small retrospective pilot cohort, GAE using IPM/CLS appeared technically feasible and safe and was associated with early pain reduction. Sustained clinically meaningful benefit at 12 months was limited to a subset of patients, indicating variable durability. These findings should be interpreted with caution and require confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.